Blake A. Morrison, vice president, Medical and Scientific Affairs, Multiple Myeloma Research Foundation, discusses the recent excitement in myeloma research. Morrison touches on the approvals of Empliciti (elotuzumab), Ninlaro (ixazomib) and Darzalex (daratumumab), as well as the research into CAR T cell immunotherapy. Read more of our coverage from the 2015 ASH Annual Meeting
